Tracking Pain in America: Patient Outcomes and Insights in an Evolving Pain Management Environment

A market research study assessing pain management trends in the United States among 1,044 patients suffering from moderate-to-severe chronic pain

Pain Insights, Inc. announces a comprehensive market research study conducted among 1,044 patients with moderate-to-severe chronic pain. This report updates “Harmonizing Clinical Practice and Clinical Guidelines in the Management of Chronic Pain: — From the Patient Perspective” published in June 2017.

Pain Insights conducted a patient-centered survey which measured patient views/satisfaction/ outcomes on the use of opioids, non-opioids, OTCs, and non-pharmacologic therapies for treatment of chronic pain.

This updated report (261 pages) to the original study also measured the impact of recent guideline recommendations on patient/practitioner views regarding opioids, the uptake of medical marijuana/cannabis, utilization of non-opioids and opioids for post-surgical pain (inpatient/outpatient).

Views on wearable devices for pain management therapy and monitoring, OTC medications, and interest in monoclonal antibody therapy against nerve growth factor are also explored.

Respondents were actively seeking care for their moderate-to-severe chronic pain from a medical practitioner and were: either currently taking an opioid (n=499), had previously taken an opioid (n=367), or were opioid naïve (n=177).

To provide context, the report includes numerous representative patient verbatim comments.

Research Goals:

  • Establish metrics to gauge awareness and impact of recent guidelines (e.g. CDC) and new policies relating to long-term opioid use
  • Ascertain the most desired patient-reported outcomes (PROs)
  • Analyze the patient journey, retrospectively and prospectively, for patients: currently taking opioids, with past opioid exposure, and opioid naïve
  • Update metrics regarding patient attitudes, experiences, and satisfaction with outcomes involving opioids, risk management, and monitoring
  • Assess awareness, perceived need, and willingness to pay for abuse-deterrent opioids
  • Explore utilization of multi-modal vs. non-opioid post-operative (ERAS) pain paradigms
  • Examine patients’ use of medical marijuana/cannabis, outcomes, and impact on opioid utilization
  • Investigate key issues such as appropriate opioid storage/disposal, in-home naloxone, use of OTC oral and topical analgesics, wearable devices, treatment of opioid-induced constipation, etc.
  • New product assessment - obtain reaction to a fair-balanced product profile for anti-NGF therapy
  • And most importantly, determine steps that can be taken to improve chronic pain therapy from the patient perspective

What is the value of this study? - The findings will lend insights into: patient engagement activities, patient-reported outcomes (PROs), educational initiatives, new product development and strategic planning strategies, target product profiles (TPPs), risk management initiatives, and market segmentation.

Drugs/drug categories included in this report:

  • Over-the-Counter analgesics (oral/topicals)
  • Nonsteroidal anti-inflammatory drugs
  • Celebrex
  • Prescription Topical NSAIDs
  • Prescription Topical Lidocaine
  • Antidepressants
  • Neuromodulators
  • Benzodiazepines
  • Muscle Relaxants
  • Corticosteroid injections
  • Hyaluronic acid injections
  • Medicinal marijuana/Cannabis
  • Immediate-release Opioids
  • Extended-release Opioids
  • Anti-Nerve growth factor (NGF)

Non-drug therapies included in this report:

  • Chiropractic manipulation
  • Acupuncture
  • Transcutaneous electrical nerve stimulation (TENS)
  • Physical therapy
  • Exercise
  • Rest or sleep
  • Biofeedback
  • Cognitive behavioral therapy (CBT)
  • Nutritional/Herbal supplements
  • Ultrasound
  • Spinal-cord stimulation (SCS)
  • Radio-frequency ablation (RFA)

The principals at Pain Insights, Inc. have researched issues pertinent to hydrocodone and the management of pain for more than 25 years. We are pleased to make this timely report available to provide you with insights into the current hydrocodone marketplace.

Download Report Details

or order complete report

To order your report or for additional details please contact:

William Kolek, President, Pain Insights, Inc. (Email)
Bob Catuosco, Vice President, Pain Insights, Inc. (Email)

Report format: PowerPoint - Executive Summary/Detailed Findings (261 pgs.)
The Powerpoint-style report will be emailed as a PDF.

Presentations available upon request.